Friday, 20 Apr 2018

You are here

The RheumNow Week in Review - 8 December 2017

Dr. Jack Cush covers the news and journal articles published on RheumNow.comin the past week.

  1. Systematic review of ULT discontinuation - 5 studies shows that ULT D/C has good short term outcomes (esp if SUA is low) but delayed relapse rates occcuring 1-4.5 yrs later - more in gout (36-81%), less w/ urolithiasis (15%). https://t.co/RTIwuH154S
  2. Prospective study of 133 IBD pts (64% CD, 36% UC) switched from Remicade to biosimilar Inflectra. After 12 mos. no differences in drug levels, disease activity between innovator and biosimilar. https://t.co/QEH3lUaXD4
  3. FDA grants orphan drug designation to SER-287 a microbiome drug to treat dysbiosis of pediatric ulcerative colitis. Will microbiome targeted therapies be the next (safe) best thing? https://t.co/PmOLeyLyy3     
  4. Patients with autoimmune connective tissue diseases (CTDs) undergoing abdominoplasty are at higher risk for certain complications (hematomas, venous thromboembolism, need for transfustions and longer hospital stays) https://t.co/AXLKNg0ag2
  5. Coffee consumption (3-4cups/day) assoc w/ 17% reduction in all cause mortality, 19% for CV mortality, 18% lower Cancer risk; but in pregnancy, high versus low/no consumption was associated with 30% increase in low birth weight and pregnancy loss (OR 1.46). https://buff.ly/2iNa7M0
  6. TWO simple tests to diagnose #Fibromyalgia in primary care: 1) for tenderness to digital pressure at 10 body sites; 2)  single question, “I have a persistent deepaching over most of my body” (0–10)  https://buff.ly/2iIx03s
  7. 2005-20014 - prevalence of one comorbidity assoc w/ pregnancy & delivery increased 50% (66.9 to 91.8 per 1,000 delivery hosp.) in the USA. The frequency of multiple chronic conditions doubled ( 4.7 to 8.1/1000 delivery) during this sameperiod. https://buff.ly/2iNuDMx
  8. Infliximab Does Not Increase Perioperative Infection 
  9. Ixekizumab (Taltz) FDA Approved for Psoriatic Arthritis 
  10. Do JAK Inhibitors Increase the Risk of Venous Thromboembolic Events? 
  11. Why TNF Inhibitors May Work in Some Autoinflammatory Patients 

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

The RheumNow Week in Review – Vitamin D Snark Report (4.20.18)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.  A second life for Syk kinase, Vitamin D talk, VTE, regulatory hearings and the Lupus clinic edge.

RheumNow Week in Review - Do you Dig Shingrix? (4.6.2018)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Highlights includes manpower shortfalls, comorbidities in AA Lupus, certolizumab pregnancy safety, which Shingles vaccine is best and the power of combination biologics in severe refractory  SLE.

"Breakthrough" Drug Designation by the FDA

The current issue of the NEJM reviews the Food and Drug Administration (FDA) “breakthrough therapy” designation that was introduced in 2012 to expedite testing and approval of medications that were intended to treat serious or life-threatening conditions.  This status is granted when preliminary evidence with a new drug suggests substantial benefits over existing therapies for these unfortunate conditions.

ACR Projects Significant Manpower Shortages for 2030

Arthritis & Rheumatology has published the results of the 2015 Workforce Study of Rheumatology Specialists, and estimates a current shortage (demand > supply) of 700 (12.9%) full-time rheumatologists and that this deficit will worsen (102%) to 4133 FTE by 2030.

RheumNow Week in Review -The Temporal Artery Biopsy Letdown (4.6.2018)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. News on the cost of RA care, infections on planes, CV events and Sacroiliitis in IBD, NXP-2 antibodies and calcinosis and rituximab in myositis ILD patients.